Journal Mobile Options
Table of Contents
Vol. 87, No. 4, 2011
Issue release date: December 2011
Urol Int 2011;87:434–438

Results of a BoNT/A Antibody Study in Children and Adolescents after Onabotulinumtoxin A (Botox®) Detrusor Injection

Schulte-Baukloh H. · Herholz J. · Bigalke H. · Miller K. · Knispel H.H.
aDepartment of Urology, St. Hedwig Hospital, Medical School of Charité Universitätsmedizin Berlin, Berlin, bInstitute of Toxicology, Medical School of Hannover, Hannover, and cDepartment of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Onabotulinumtoxin A (OnaBoNT/A, Botox®) is effective in the treatment of neurogenic detrusor overactivity, however this therapy can fail. In a prospective study, we analyzed patient serum for BoNT/A antibodies (BoNT/A-AB) as a possible cause of therapy failure. Methods: 17 patients (average age 14.5 years) who had neurogenic detrusor overactivity were admitted for repeated OnaBoNT/A injection into the detrusor muscle. We analyzed their serum for BoNT/A-AB. The clinical findings were correlated with the incidence of BoNT/A-AB. Results: Positive BoNT/A-AB were clearly or marginally determined in 6 patients. Therapy had failed in all 6. In 4 of the 6, therapy might have failed because of a low-compliance bladder (3 patients) or tethered-cord syndrome (1), but BoNT/A-AB were found as the only possible cause in 2 patients. Thus, the incidence of BoNT/A-AB in the 17 patients was 35%, and the antibodies were clinically significant in 12%. All patients with BoNT/A-AB had a history of recurrent urinary tract infections. Conclusions: Patients who show a failure of therapy after OnaBoNT/A injections for which no other causes can be determined should have their serum checked for BoNT/A-AB. Recurrent urinary tract infection might be a predisposing factor for BoNT/A-AB.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH: Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003;44:139–143.
  2. Hoebeke P, De Caestecker K, Vande Walle J, et al: The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 2006:176:328–330.
  3. Dressler D: Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004:19:92–100.

    External Resources

  4. Comella CC, Chicago IL, Jankovic J: Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type a treatment for cervical dystonia. Neurology 2004:62(suppl):poster 06.141.
  5. Schulte-Baukloh H, Bigalke H, Miller K, et al: Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008:15:407–415.
  6. Dressler D, Dirnberger G, Bhatia KP: Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 2000:15:973–976.
  7. Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002:21:167–178.
  8. Grosse J, Kramer G, Stohrer M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005:47:653–659.
  9. Bigalke H: Immunological properties of botulinum neurotoxins. Personal communication, 2009.
  10. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H: Botulinum-A toxin therapy: neutralizing and non-neutralizing antibodies – therapeutic consequences. Exp Neurol 1997:147:96–102.
  11. Hegele A, Varga Z, Frohme C, Olbert P, Hofmann R: Antibodies after BTX-A application in the detrusor muscle in patients with OAB: frequency and clinical significance. Urologe 2010;49(suppl):89, poster 11.5.
  12. Kajbafzadeh AM, Nikfarjam L, Mahboubi AH, Dianat S: Antibody formation following botulinum toxin type A (Dysport®) injection in children with intractable bladder hyper-reflexia. Urology 2010;76:233–237.
  13. Lazzeri M: The physiological function of the urothelium – more than a simple barrier. Urol Int 2006:76:289–295.
  14. Kromminga A, Schellekens H: Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann NY Acad Sci 2005:1050:257–265.
  15. Dressler D, Bigalke H: Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord 2002:17:170–173.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50